Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607953 · ClinicalTrials.gov registry record · Phase 1
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
A Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma, sponsored by TriSalus Life Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05607953: Active Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma, sponsored by TriSalus Life Sciences.
NCT05607953 is a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma that is active but no longer recruiting, run by TriSalus Life Sciences. The registered enrollment target is 60 participants, roughly in line with the 64-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05607953, a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by TriSalus Life Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with locally advanced pancreatic cancer.
Primary Outcome
As a measure of safety, adverse events will be graded according to CTCAE v5.0
Conditions Studied
Interventions
- DRUG SD-101
- BIOLOGICAL anti-PD-1
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What the registry record for NCT05607953 still lists
NCT05607953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 64-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target.
The record links to 1 condition, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which SD-101 is the first listed.
NCT05607953 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05607953 about?
NCT05607953 is a clinical study titled "Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma". This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with locally advanced pancreatic cancer.
What is the current status of trial NCT05607953?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-03-01. Estimated completion is 2027-10.
What conditions does trial NCT05607953 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT05607953?
The interventions under investigation include: SD-101 (DRUG), anti-PD-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05607953?
This trial is sponsored by TriSalus Life Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607953 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05607953's enrollment target sits among peer trials
60 6th of 18 higher than 13 of 18 other Locally Advanced Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Locally Advanced Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
RECRUITING · Phase 1
-
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
RECRUITING · Phase 1
-
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
BATs Treatment for Pancreatic Cancer, Phase Ib/II
ACTIVE NOT RECRUITING · Phase 1
-
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI